Abstrakt: |
A recent study conducted at the Institute of Hematology and Transfusion Medicine in Warsaw, Poland, has focused on acute myeloid leukemia (AML), a type of aggressive blood cancer. The study highlights the role of the TP53 gene in AML, which is involved in various cellular functions and is mutated in 5%-12% of AML cases. Patients with TP53 mutations have a poor prognosis and shorter overall survival, even with aggressive treatment. The study explores the molecular characteristics of TP53-mutated AML, its impact on leukemia hallmarks such as metabolism and immune evasion, and the development of therapeutic strategies for this specific subgroup of patients. [Extracted from the article] |